Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer's disease: prevalence, plasma cholesterol levels and cerebrovascular change.
The prevalence of the apolipoprotein E-4 allele (ApoE-4) was significantly higher in a referral population of 40 patients with clinically diagnosed Alzheimer's disease than in a sample of non-demented elderly controls (P < 0.01). The highest plasma cholesterol levels were found in demented patients homozygotic for Apo E-4, but no significant increases of glucose, triglycerides and thyroxine or of leuko-araiosis and brain infarcts were verified in this preliminary study.
Czech
C
C
Center for Molecular Biology, Heidelberg, Germany.
Förstl
H
H
Hentschel
F
F
Mönning
U
U
Besthorn
C
C
Geiger-Kabisch
C
C
Sattel
H
H
Masters
C
C
Beyreuther
K
K
D000368:Aged; D000483:Alleles; D000544:Alzheimer Disease / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D001921:Brain / Q000473:pathology*; D002544:Cerebral Infarction / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D002784:Cholesterol / Q000097:blood*; D002888:Chromosomes, Human, Pair 19; D005260:Female; D006580:Genetic Carrier Screening; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D002784:Cholesterol